Pitch: a startup producing bovine and human lactoferrin through precision fermentation for nutrition and health applications.

Source: All G

ID card

• HQ: Australia
• Founded: 2020
• Funding: A$46.7M (~ $32.8M)
• Last Funding: pre-Series B with ****undisclosed amount (08/2026)
• Corporate Investors: Döhler, Armor Protéines (Savencia)
• Partnerships: Döhler, JV with Armor Protéines (Savencia), Liberation Labs, Cauldron
• Innovations: Precision fermentation to produce lactoferrin (bovine and human) and human casein
• Competitors: Vivici (Netherlands), De Novo FoodLabs (UK), ****Helaina (US), TurtleTree (Singapore), Pinnacle Food Group (Canada), Eclipse Ingredients (Australia)
• Regulation:
  • US : “No questions letter” from the FDA for its recombinant bovine lactoferrin.
  • China: Regulatory clearance for recombinant bovine lactoferrin.

More insights

• LFX, its first commercial ingredient, is an bovine lactoferrin with above 95% purity produced through precision fermentation which:
  • is now available in the US following an FDA “no questions” letter.
  • targets functional foods & beverages and dietary supplements, with applications across active nutrition, gut health, healthy ageing, women’s health and immune support.
  • is separately pursuing US approval for infant formula.
• For production and commercialisation, All G relies on multiple industrial partners:
  • JV with Armor Protéines (owned by Savencia) to produce and commercialise recombinant bovine and human lactoferrin.
  • Döhler for pilot plant construction and distribution.
  • CDMOs Liberation Labs (US) and Cauldron (Australia) to expand fermentation capacity.
  • Chinese CMO currently producing multiple tonnes annually, while All G explores a second European facility.
• All G is also expanding beyond bovine lactoferrin into:
  • Human lactoferrin: to target infant nutrition and women’s health, with self-affirmed GRAS (for the end of 2026) and market launch planned by early 2027.
  • Human beta-casein: for infant nutrition, supported by an A$1.1M government grant.
• The startup claims its technology answers bottlenecks of conventional lactoferrin including production, notably purity and glycosylation.

For Symrise

Why did we select the startup?

• All G is one of the most advanced startups producing lactoferrin through precision fermentation.
• Its expansion into human lactoferrin and human beta-casein, with applications spanning women’s health and infant nutrition, also makes it relevant for Symrise's health, nutrition and functional ingredient activities.

Source: All G

Why now?

All G is entering commercial scale-up and international expansion following the US launch of LFX, while exploring additional production in Europe leveraging its partnerships Armor Protéines and Döhler, alongside expansion in Southeast Asia.